| The effects of nefopam on the gain and maximum intensity of shivering in healthy volunteers. | |
| | |
MedLine Citation:
|
PMID: 20529984 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Mild hypothermia has been shown to improve neurologic outcome after cardiac arrest. Nefopam, a centrally acting, nonsedative analgesic, decreases the threshold of shivering, but not vasoconstriction, and thus might be a suitable drug for induction of therapeutic hypothermia. However, not only the threshold but also the gain and maximum intensity of shivering define the thermoregulatory properties of a drug and thus are clinically important. Therefore, we evaluated the gain and maximum intensity of shivering at 2 different doses of nefopam and placebo. METHODS: Seven healthy volunteers were randomly assigned to 3 study days: (1) control (saline), (2) small-dose nefopam (50 ng/mL), and (3) large-dose nefopam (100 ng/mL). On all study days volunteers were cooled using central venous infusion of cold IV fluid while mean skin temperature was maintained at 31 degrees C. Core temperature was recorded at the tympanic membrane. Threshold, gain, and maximum intensity of shivering were evaluated using oxygen consumption. RESULTS: Both 50 and 100 ng/mL nefopam significantly reduced the shivering threshold as well as the gain of shivering: shivering threshold: 35.6 degrees C + or - 0.2 degrees C (control); 35.2 degrees C + or - 0.3 degrees C (small dose); 34.9 degrees C + or - 0.5 degrees C (large dose), P = 0.004; gain of shivering: 597 + or - 235 mL x min(-1) x degrees C(-1) (control); 438 + or - 178 mL x min(-1) x degrees C(-1) (small dose); 301 + or - 134 mL x min(-1) x degrees C(-1) (large dose), P = 0.028. Maximum intensity of shivering did not differ among the 3 treatments. CONCLUSIONS: Nefopam significantly reduced the gain of shivering. This reduction, in combination with a reduced shivering threshold, will allow clinicians to cool patients even further when therapeutic hypothermia is indicated. |
| | |
Authors:
|
Yoshie Taniguchi; Syed Z Ali; Oliver Kimberger; Sandra Zmoos; Rolf Lauber; Monica Markstaller; Andrea Kurz |
Related Documents
:
|
11459414 - A xylazine infusion regimen to provide analgesia in sheep. 8786284 - Thyrotropin-releasing hormone (trh) and cns regulation of anorectal motility in the rat. 21932164 - A phase i trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil f... 18989344 - Intralesional and sub-tenon's infusion of corticosteroids for treatment of refractory p... 17229894 - The triglyceride-lowering effects of a modest dose of docosahexaenoic acid alone versus... 23357844 - Pharmacokinetic and tolerability of i.m. disodium clodronate 200 mg/lidocaine 1%, given... |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial Date: 2010-06-07 |
Journal Detail:
|
Title: Anesthesia and analgesia Volume: 111 ISSN: 1526-7598 ISO Abbreviation: Anesth. Analg. Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-07-28 Completed Date: 2010-08-26 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 1310650 Medline TA: Anesth Analg Country: United States |
Other Details:
|
Languages: eng Pagination: 409-14 Citation Subset: AIM; IM |
Affiliation:
|
Department of Outcomes Research, Anesthesia Institute, Cleveland Clinic, Cleveland, OH 43195, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Analgesics, Non-Narcotic / administration & dosage*, blood Blood Pressure / drug effects Female Heart Rate / drug effects Humans Hypothermia, Induced / methods* Male Nefopam / administration & dosage*, blood Oxygen Consumption / drug effects Sensory Thresholds / drug effects* Shivering / drug effects* Skin Temperature / drug effects Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Analgesics, Non-Narcotic; 13669-70-0/Nefopam |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A Prospective, Double-Blinded, Randomized, Clinical Trial Comparing the Efficacy of 40 Mg and 60 Mg ...
Next Document: Ongoing provision of individual clinician performance data improves practice behavior.